What's new

Opinion on medicine for use outside EU: Mosquirix, RTS,S [Portion of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)], Malaria, 23/07/2015 Positive opinion

Opinion on medicine for use outside EU: Mosquirix, RTS,S [Portion of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)], Malaria, 23/07/2015 Positive opinion

May 5, 2025 - 14:45
 0
Opinion on medicine for use outside EU: Mosquirix, RTS,S [Portion of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)], Malaria, 23/07/2015 Positive opinion
Opinion on medicine for use outside EU: Mosquirix, RTS,S [Portion of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)], Malaria, 23/07/2015 Positive opinion
Read More

Tags:

Previous Article

FDA will ask outside experts to review Capricor’s therapy for Duchenne muscular ...

Next Article

RBS hires new HR director

Related Posts

Orphan designation: octreotide hydrochloride Treatment of acromegaly, 12/06/2009 Positive

Orphan designation: octreotide hydrochloride Treatment...

Apr 25, 2025  0

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

May 2, 2025  0

Business process description for certificates of medici...

Apr 22, 2025  0